JP Morgan Chase’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.9M | Buy |
1,093,026
+113,727
| +12% | +$8.3M | 0.01% | 1078 |
|
|
2026
Q1 | $44.5M | Buy |
979,299
+916,348
| +1,456% | +$34.5M | ﹤0.01% | 1467 |
|
|
2025
Q4 | $2.06M | Sell |
62,951
-213,033
| -77% | -$5.57M | ﹤0.01% | 4046 |
|
|
2025
Q3 | $4.63M | Buy |
275,984
+228,705
| +484% | +$3.73M | ﹤0.01% | 3438 |
|
|
2025
Q2 | $708K | Buy |
47,279
+5,723
| +14% | +$84.7K | ﹤0.01% | 4592 |
|
|
2025
Q1 | $671K | Buy |
41,556
+6,308
| +18% | +$131K | ﹤0.01% | 4593 |
|
|
2024
Q4 | $821K | Buy |
35,248
+5,775
| +20% | +$169K | ﹤0.01% | 4762 |
|
|
2024
Q3 | $867K | Buy |
29,473
+6,701
| +29% | +$187K | ﹤0.01% | 4555 |
|
|
2024
Q2 | $535K | Buy |
22,772
+22,761
| +206,918% | +$768K | ﹤0.01% | 4657 |
|
|
2024
Q1 | $417 | Sell |
11
-30
| -73% | -$869 | ﹤0.01% | 6743 |
|
|
2023
Q4 | $882 | Hold |
41
| – | – | ﹤0.01% | 6851 |
|
|
2023
Q3 | $502 | Sell |
41
-2
| -5% | -$26 | ﹤0.01% | 6728 |
|
|
2023
Q2 | $481 | Hold |
43
| – | – | ﹤0.01% | 6551 |
|
|
2023
Q1 | $0 | Hold |
43
| – | – | ﹤0.01% | 7208 |
|
|
2022
Q4 | $0 | Sell |
43
-103
| -71% | -$1.85K | ﹤0.01% | 6985 |
|
|
2022
Q3 | $2K | Buy |
146
+53
| +57% | +$655 | ﹤0.01% | 6266 |
|
|
2022
Q2 | $1K | Sell |
93
-904
| -91% | -$31.7K | ﹤0.01% | 6382 |
|
|
2022
Q1 | $58K | Buy |
997
+162
| +19% | +$13.6K | ﹤0.01% | 5739 |
|
|
2021
Q4 | $99K | Buy |
835
+68
| +9% | +$10.7K | ﹤0.01% | 5688 |
|
|
2021
Q3 | $152K | Sell |
767
-2,738
| -78% | -$479K | ﹤0.01% | 5367 |
|
|
2021
Q2 | $610K | Buy |
3,505
+2,345
| +202% | +$426K | ﹤0.01% | 4575 |
|
|
2021
Q1 | $230K | Sell |
1,160
-24
| -2% | -$4.61K | ﹤0.01% | 5092 |
|
|
2020
Q4 | $233K | Buy |
1,184
+558
| +89% | +$116K | ﹤0.01% | 4758 |
|
|
2020
Q3 | $111K | Buy |
626
+61
| +11% | +$11.3K | ﹤0.01% | 4643 |
|
|
2020
Q2 | $131K | Sell |
565
-743
| -57% | -$142K | ﹤0.01% | 4457 |
|
|
2020
Q1 | $152K | Sell |
1,308
-630
| -33% | -$107K | ﹤0.01% | 4381 |
|
|
2019
Q4 | $371K | Sell |
1,938
-256
| -12% | -$50.2K | ﹤0.01% | 4385 |
|
|
2019
Q3 | $422K | Buy |
2,194
+56
| +3% | +$10.9K | ﹤0.01% | 4246 |
|
|
2019
Q2 | $343K | Buy |
2,138
+1,871
| +701% | +$323K | ﹤0.01% | 4411 |
|
|
2019
Q1 | $53K | Buy |
267
+99
| +59% | +$20.6K | ﹤0.01% | 5109 |
|
|
2018
Q4 | $32K | Sell |
168
-1,660
| -91% | -$352K | ﹤0.01% | 5222 |
|
|
2018
Q3 | $437K | Sell |
1,828
-2,973
| -62% | -$694K | ﹤0.01% | 4339 |
|
|
2018
Q2 | $1.27M | Buy |
4,801
+2,775
| +137% | +$683K | ﹤0.01% | 3691 |
|
|
2018
Q1 | $502K | Buy |
2,026
+1,784
| +737% | +$322K | ﹤0.01% | 4010 |
|
|
2017
Q4 | $33K | Buy |
242
+234
| +2,925% | +$28.6K | ﹤0.01% | 5030 |
|
|
2017
Q3 | $1K | Sell |
8
-43
| -84% | -$4.03K | ﹤0.01% | 4914 |
|
|
2017
Q2 | $5K | Buy |
+51
| New | +$7.05K | ﹤0.01% | 4761 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
JP Morgan Chase's SYRE Position: Q2 2026 in Review
JP Morgan Chase increased its Spyre Therapeutics (SYRE) stake by 12% in Q2 2026, buying an estimated $8.3M and bringing the position to 1,093,026 shares worth $98.9M. The position accounts for 0.01% of the portfolio, ranked #1078.
JP Morgan Chase first reported a position in SYRE in Q2 2017 and has held it in 37 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- JP Morgan Chase held 1,093,026 shares of Spyre Therapeutics worth $98.9M as of Q2 2026.
- JP Morgan Chase bought 113,727 Spyre Therapeutics shares in Q2 2026, an estimated $8.3M.
- Spyre Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1078 holding.
- JP Morgan Chase first reported a position in Spyre Therapeutics in Q2 2017 and has held it in 37 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.